Efficacy and Safety of Recombinant Human Nerve Growth Factor in Patients With Diabetic Polyneuropathy

2000357 citationsJournal Article

Authors

Stuart C. Apfel

Sherwin Schwartz · Diabetes & Glandular Disease Clinic

Bruce T. Adornato

Roy Freeman · Harvard University Press

Victor Biton · Hadassah Medical Center

Marc Rendell

Aaron I. Vinik · Eastern Virginia Medical School

Michael J. Giuliani · University of Pittsburgh

Abstract

Unlike previous phase 2 trials, this phase 3 clinical trial failed to demonstrate a significant beneficial effect of rhNGF on diabetic polyneuropathy. JAMA. 2000;284:2215-2221.

Topics & Keywords

Botulinum Toxin and Related Neurological Disorders Pain Mechanisms and Treatments Nerve injury and regeneration

UN Sustainable Development Goals

Good health and well-being

Publication Details

Published in: JAMA

Volume 284, Issue 17, pp. 2215-2215

DOI: 10.1001/jama.284.17.2215

Field-Weighted Citation Impact: 14.25